News >

ASCO Updates Treatment Guidelines for Advanced NSCLC

Jason Harris
Published: Tuesday, Aug 15, 2017

Nasser Hanna, MD

Nasser Hanna, MD
ASCO has updated its guidelines for first- and second-line treatment of patients with stage IV non–small cell lung cancer (NSCLC). The organization has created new recommendations regarding the use of immunotherapy, and updated advice on targeted therapies for patients with mutations in the EGFR, ALK, or ROS1 genes.

The organization also noted that while immunotherapy can provide a survival benefit in some cases, not every patient will respond to treatment, and physicians still do not fully understand optimal sequencing of immune checkpoint therapy and other recommended agents.
Hanna N, Johnson D, Temin S, et al. Systemic therapy for stage IV non–small-cell lung cancer: American Society of Clinical Oncology clinical practice guideline update [published online August 14, 2017]. J Clin Oncol. doi: 10.1200/JCO.2017.74.6065.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Advances in™ Therapies for Patients With ALK-Positive Lung Cancers: More Options…More Decisions…Better OutcomesAug 30, 20191.5
Publication Bottom Border
Border Publication
x